Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TMJ premarket applications based on historically controlled studies urged by TMJ Implants, Inc..

This article was originally published in The Gray Sheet

Executive Summary

USE OF NON-RANDOMIZED, HISTORICALLY CONTROLLED STUDIES IN TMJ PMA submissions is urged by temporomandibular joint implant manufacturer TMJ Implants, Inc. in recent comments to FDA. Responding to FDA's July proposed call for premarket approval applications for partial and total TMJ prostheses, TMJ Implants notes that the preamendments devices have been marketed for over 30 years and "over this time" have become "an acceptable treatment regimen." Therefore, the firm reasons, a randomized trial with a concurrent control is not feasible since it would be impossible "to ask a physician to randomize a patient to [an alternative] treatment regimen that over time has shown to not be the treatment of choice in treating TMJ disorders."

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts